叶黄素
医学
奥沙利铂
伊立替康
新辅助治疗
养生
置信区间
肿瘤科
放射治疗
胰腺癌
内科学
外科
癌症
结直肠癌
乳腺癌
作者
Fausto Petrelli,Andrea Coinu,Karen Borgonovo,Mary Cabiddu,Mara Ghilardi,Veronica Lonati,Enrico Aitini,Sandro Barni
出处
期刊:Pancreas
[Lippincott Williams & Wilkins]
日期:2015-04-14
卷期号:44 (4): 515-521
被引量:173
标识
DOI:10.1097/mpa.0000000000000314
摘要
The use of neoadjuvant chemotherapy can enable surgical resection of borderline resectable or unresectable pancreatic cancer (PC). The aim of this study was to evaluate the effectiveness of the multiagent 5-fluorouracil + oxaliplatin + irinotecan + leucovorin (FOLFIRINOX) regimen as a neoadjuvant treatment for PC.Studies in which FOLFIRINOX with or without radiotherapy was given before surgery to patients with borderline resectable or unresectable PC were analyzed using a meta-analytical approach. The primary outcomes were resection rate and radical (R0) resection rate. Data were expressed as weighted pooled proportions with 95% confidence intervals (CIs).Thirteen studies, with a total of 253 patients, were included in this meta-analysis. After undergoing the treatment, 43% (95% CI, 32.8-53.8) of patients were resected and 39.4% (95% CI, 32.4-46.9) underwent R0 resection (85% of surgical specimens). In particular, among borderline resectable PCs, R0 resection was possible in 63.5% (95% CI, 49%-76%) of the cases. The rate of R0 resection in unresectable PCs was 22.5% (95% CI, 13.3-35.4).This meta-analysis shows that down-staging after neoadjuvant FOLFIRINOX-based therapy is noticeable in patients with borderline resectable/unresectable PC, with a total R0 resection rate of 40%.
科研通智能强力驱动
Strongly Powered by AbleSci AI